Invitation to attend a teleconference on July 2, 1.30 pm CET - DTx US commercialization plan
Uppsala, Sweden – July 2, 2020 – Due to today´s announcement the US launch of deprexis® and vorvida® has been initiated and the decision to accelerate the launch of the company´s full digital offering, also incl. OXD01, analysts, investors and media are welcome to attend a teleconference today at 1.30 pm CET. On the call Nikolaj Sørensen, President and CEO and Dennis Urbaniak, EVP Digital Therapeutics, will provide a short presentation on the commercialization plans for the digital therapies and answer questions. Questions can also be sent in advance to [email protected], no later than 11.00 am CET. Please view the instructions below on how to participate.
Dial in number: SE: +46 8 566 42 707, UK: +44 33 330 09 271, US: +1 83 382 305 86 (no code needed)
The presentation can be downloaded from the company´s website approximately one hours ahead of the presentation at, https://orexo.com/investors/reports-presentations-and-audiocasts/
For more information please contact:
|Lena Wange, IR & Communications Director|
|Tel: +46 18 780 88 00|
|E-mail: [email protected]|